ReviewTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015
Breast cancer circulating biomarkers: advantages, drawbacks, and new insights.
Review in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Diagnostic Value of Concentration of Circulating Cell-Free DNA in Breast Cancer: A Meta-Analysis.Frontiers in oncology · 2019Pooled it
- Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility.International journal of molecular sciences · 2017Pooled it
- Resting State of Dementia of the Alzheimer's Type and Healthy Older Adults Using fNIRS.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025Article
- Markers of Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: New in Molecular Oncology.Asian Pacific journal of cancer prevention : APJCP · 2024Review
- Review
- DNA-Directed Protein Anchoring on Oligo/Alkanethiol-Coated Gold Nanoparticles: A Versatile Platform for Biosensing Applications.Nanomaterials (Basel, Switzerland) · 2022Article
- Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years).Cancer biomarkers : section A of Disease markers · 2021Article
- Serum miRNA-based distinct clusters define three groups of breast cancer patients with different clinicopathological and immune characteristics.Cancer immunology, immunotherapy : CII · 2019Article
- XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients.Frontiers in oncology · 2019Article
- Model based on GA and DNN for prediction of mRNA-Smad7 expression regulated by miRNAs in breast cancer.Theoretical biology & medical modelling · 2018Article
- Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers.Cancer management and research · 2018Review
- Evidence on the cost of breast cancer drugs is required for rational decision making.Ecancermedicalscience · 2018Article
- Prognostic Impact of the Tumor Marker CA 15-3 in Patients With Breast Cancer and Bone Metastases Treated With Palliative Radiotherapy.Journal of clinical medicine research · 2017Article
- A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer.Annals of surgical treatment and research · 2017Article
- Progress in the clinical detection of heterogeneity in breast cancer.Cancer medicine · 2016Review
- Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As of today, the level of individualization of cancer therapies has reached a level that 20 years ago would be considered visionary. However, most of the diagnostic, prognostic, and therapy-predictive procedures which aim to improve the overall level of personalization are based on the evaluation of tumor tissue samples, therefore requiring surgical operations with consequent low compliance for patients and high costs for the hospital. Hence, the research of a panel of circulating indicators which may serve as source of information about tumor characteristics and which may be obtainable by a simple withdrawal of peripheral blood today represents a growing field of interest. This review aims to objectively summarize the characteristics of the currently available breast cancer circulating biomarkers, also providing an overview about the multitude of novel potential soluble predictors which are still under evaluation. Specifically, the usefulness of a so-called "liquid biopsy" will be discussed in terms of improvements of diagnosis, prognosis, and therapy-prediction, but an overview will be given also on the potentiality of the molecular characterization arising from the isolation of circulating biomarkers and cells. Although this review will focus on the specific case of the breast, in the future liquid biopsies will hopefully be available for virtually any type of neoplasms.
Indexed as
Identifiers
26307395What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.